title: Efficacy, safety, and palatability of RACTAB(®) formulation amlodipine orally disintegrating tablets.
abstract: OBJECTIVE
  The aim of this study was to confirm the efficacy, safety, and expected palatability of amlodipine orally disintegrating tablets (ODT) [RACTAB(®) formulation (Towa, Osaka, Japan)]. We report the re-analyzed results of 1687 cases in clinical settings obtained through postmarketing surveillance in Japan.
  
  
  METHODS
  Study subjects were patients receiving treatment for the first time with amlodipine ODT for hypertension under routine care. A multicenter central registration system was used for this prospective survey. The survey was conducted from October 2008 to October 2010. The observational period was 12 weeks, during which time surveys on outpatient blood pressure, adverse events, palatability, etc. were conducted.
  
  
  RESULTS
  Blood pressure stabilized following treatment, and both systolic and diastolic blood pressures were favorably controlled. Adverse events observed were not significantly different from those observed during drug use trials of amlodipine formulations reported in 2003. Moreover, palatability of amlodipine ODT showed a 99.6% (227 of 228 cases) favorable patient acceptance, which is consistent with the initial design concept of RACTAB(®) formulation.
  
  
  CONCLUSIONS
  The results of this postmarketing surveillance study indicated that the efficacy, safety, and palatability of amlodipine ODT met our expectations (dissolves quickly in the mouth, tastes good, and is not rough on the tongue). Accordingly, amlodipine ODT are believed to be an easy-to-use formulation for prescribing doctors, dispensing pharmacists, and patients receiving treatment.
authors: Towa Pharmaceutical Co., Ltd., Osaka, Japan.
authors: Mari
authors: M
authors: Fukui-Soubou
authors: Hirotaka
authors: H
authors: Terashima
authors: Kiyoshi
authors: K
authors: Kawashima
authors: Osamu
authors: O
authors: Utsunomiya
authors: Taichiroh
authors: T
authors: Terada
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D017311:Amlodipine / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry*; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D004355:Drug Stability; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009422:Nervous System Diseases / Q000139:chemically induced / Q000453:epidemiology; D011446:Prospective Studies; D013649:Taste / Q000187:drug effects* / Q000502:physiology; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D017311:Amlodipine